Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,888JPY
19 Oct 2018
Change (% chg)

¥19 (+1.02%)
Prev Close
¥1,870
Open
¥1,856
Day's High
¥1,892
Day's Low
¥1,852
Volume
4,262,300
Avg. Vol
7,147,474
52-wk High
¥2,056
52-wk Low
¥1,380

Select another date:

Wed, Aug 22 2018

Photo

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Aug 22 Drugmakers Pfizer Inc and Astellas Pharma Inc said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

BRIEF-FDA Approves Supplemental New Drug Application For Myrbetriq For Treatment Of Overactive Bladder Symptoms

* FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR MYRBETRIQ® (MIRABEGRON) FOR USE IN COMBINATION WITH SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31

BRIEF-Astellas Says To Cancel Treasury Stock Equivalent To 4.3 Percent Of Shares Outstanding

* ASTELLAS SAYS TO CANCEL TREASURY STOCK EQUIVALENT TO 4.3 PERCENT OF SHARES OUTSTANDING Further company coverage: (Reporting By Chris Gallagher)

BRIEF-Astellas Pharma Submits NDA For Approval Of Gilteritinib

* ASTELLAS SUBMITS NEW DRUG APPLICATIONS FOR APPROVAL OF GILTERITINIB FOR THE TREATMENT OF FLT3MUT+ RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement

* PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014

Select another date: